|
AEVIS VICTORIA SA / Key word(s): Preliminary Results Ad hoc announcement pursuant to Art. 53 LR Fribourg, 30 July 2024 AEVIS VICTORIA SA (AEVS:SW) achieved revenues of more than CHF 450 million in the first half-year 2024 AEVIS VICTORIA SA (AEVIS) continued its positive development and achieved revenues of more than CHF 450 million in the first six months of 2024, significantly up compared to the previous year (CHF 428 million). Consolidated EBITDA should rise by more than 25% to reach between CHF 40 and 45 million. Both operating divisions, Swiss Medical Network and MRH Switzerland AG (ex-Victoria Jungfrau AG), contributed to the pleasing development. Swiss Medical Network realizing net revenues of more than CHF 350 million, up from CHF 334 million last year, particularly due to a return to normal activity at the Clinique de Genolier following the completion of construction work for the Genolier Innovation Hub, which will be inaugurated on 27 September 2024. At the same time, the implementation of various cost optimization measures contributed CHF 6 million to the improvement in margins. MRH Switzerland AG continued to grow, with revenues of almost CHF 100 million, compared to CHF 88 million last year, with the hotels in Davos and Interlaken achieving double-digit growth above the industry average. AEVIS will publish its 2024 Half-year Report on 19 September 2024. For further information: AEVIS VICTORIA SA - Investing for a better life End of Inside Information |
1955751 30-Jul-2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
Special
